Navigation Links
Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
Date:5/7/2008

this evaluation."

With the addition of SBI-087 -- Trubion's next-generation, fully humanized CD20-directed SMIPTM -- Trubion's pipeline now includes two compounds under development for the treatment of autoimmune and inflammatory diseases. Trubion and Wyeth are leveraging Trubion's SMIPTM technology to create a portfolio of product candidates with customized mechanisms of action in an effort to optimize patient safety, efficacy and convenience.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Israel , June 19, 2013 ... a phase I study in volunteers, and preliminary results ... of ND0612, were presented at the 2013 International Congress ... proprietary levodopa/carbidopa liquid drug formula under development for continuous ... maintain constant levodopa plasma concentrations. ND0612 has ...
(Date:6/19/2013)...   Life Technologies Corporation (NASDAQ: ... Suzhou Ribo Life Sciences (Ribo) the exclusive rights ... China using Life,s Invivofectamine® Rx ... in combination with Invivofectamine® Rx to create a ... high unmet medical need in the Chinese healthcare ...
(Date:6/19/2013)... Juni 2013 Specialty Coating ... Entwicklung von SCS microRESIST™, einer antimikrobiellen ... Beschichtung mit Parylene gelungen ist. SCS ... Parylene mit antimikrobiellen Eigenschaften und erlaubt ... auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... TARRYTOWN, N.Y. and BERLIN, April 8, 2011 ... and Bayer HealthCare today announced that they have initiated ... the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic ... certain eye diseases, in the treatment of Diabetic Macular ...
... Texas, April 7, 2011 Assured Pharmacy (APHY: pinksheets), ... more than 3,000 sufferers of chronic pain, has filed ... to effect a 1-for-180 reverse stock split of the ... reverse stock split in the number of issued and ...
Cached Medicine Technology:Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 2Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 3Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 4Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 5Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 6Assured Pharmacy Announces Reverse Stock Split 2Assured Pharmacy Announces Reverse Stock Split 3
(Date:6/19/2013)... CCA , America's leader in partnership corrections, ... President, Health Services, effective June 8, 2013. Dr. ... CCA. He will replace the retiring Herb Spiwak. ... lead CCA's dedicated team of health care professionals. ... our partners as we provide effective care to persons ...
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 According to a ... Surviving Weekend Sunburn,” it is not uncommon for a person ... summer months. A person is likely to forget to reapply ... which is both dry and itchy. When this occurs, it ... to goo.gl/gDyjP). , “Most people do not realize that milk ...
(Date:6/19/2013)... online edition of the journal Nature , a ... California, San Diego School of Medicine visually monitored the ... occurs in zebrafish after cardiac ventricular injury. Their ... heart are more plastic, or capable of transformation into ... the research reveals a novel potential source of cells ...
(Date:6/19/2013)... Spanish . ... goes by the name of the 10/90 gap: only 10 ... that accounted for 90 per cent of the global disease ... for Neglected Diseases initiative (DNDi) came into being in 2003. ... granted the BBVA Foundation Frontiers of Knowledge Award in the ...
Breaking Medicine News(10 mins):Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Skin Care – How to treat Sunburn 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... French . , Montreal, March 11, 2009 ... influence of cannabis (DUIC) and engage in reckless driving, according ... the journal Accident Analysis and Prevention , men who ... consider taking the wheel after consuming cannabis more often than ...
... 11 On Friday, March 6, 2009, Coast ... Justice, the FBI, the FDA, and the Commonwealth of Virginia ... Independent Review Board discovered that a protocol submitted for review ... of Clifton, Virginia, was fraudulent in violation of federal and ...
... most progressive benefit management firms, today announced a strategic partnership with ... will enable CBCA to provide an unparalleled suite of proven care ... ... OH (Vocus) March 11, 2009 -- CBCA Administrators, Inc. (CBCA), one ...
... LOS ANGELES, March 11 MMR Information ... through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ... Records ("PHRs") ( www.mymedicalrecords.com ) and electronic ... ), announced that it has selected Gene ...
... March 11 The U.S. Agency for ... in Southern Africa launched a new program to reduce ... and Mpumalanga Provinces. The three-year, $5.1 million project is ... Relief (PEPFAR), and administered by USAID . A ...
... researchers wanted to know whether an increased CO2 ... therefore examined freshwater micro-algae: small, floating and mostly ... tanks called limnotrons. These were aerated with ordinary ... of CO2. The researchers then examined the ratio ...
Cached Medicine News:Health News:Study finds cannabis use, dangerous driving behaviors interrelated 2Health News:Clinical Trial Fraud Exposed by Coast IRB 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 2Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 4Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 5Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2
Each handle is designed to fit a specific trephine size....
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Medicine Products: